Proteomic Analysis Shows Constitutive Secretion of MIF and p53-associated Activity of COX-2-/- Lung FibroblastsGENOMICS PROTEOMICS & BIOINFORMATICSIF7.92017-12-136OAAI
Genomic, Lipidomic and Metabolomic Analysis of Cyclooxygenase-null Cells: Eicosanoid Storm, Cross Talk, and Compensation by COX-1GENOMICS PROTEOMICS & BIOINFORMATICSIF7.92016-03-2112OAAI
Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: Reversal by celecoxibIMMUNOLOGY LETTERSIF2.82013-04-0114PREAI
Glatiramer acetate (GA), the immunomodulatory drug, inhibits inflammatory mediators and collagen degradation in osteoarthritis (OA) cartilageOSTEOARTHRITIS AND CARTILAGEIF92011-09-014OA
GLATIRAMER ACETATE (GA), A PEPTIDE IMMUNOMODULATORY DRUG, INHIBITS INFLAMMATORY MEDIATORS, MMP-13 ACTIVITY AND COLLAGEN DEGRADATION IN OA CARTILAGEOSTEOARTHRITIS AND CARTILAGEIF92010-10-010OAAI
Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage:: Evidence for signaling via the EP4 receptorJOURNAL OF IMMUNOLOGYIF3.42008-10-01200OAAI
F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-β activationFASEB JOURNALIF4.22008-09-0959OAAI
Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine (vol 10, pg 1, 2002)OSTEOARTHRITIS AND CARTILAGEIF92003-09-011OAAI
Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicineOSTEOARTHRITIS AND CARTILAGEIF92002-01-01153OAAI
Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type IIIL-1 decoy receptor - Potential for pharmacological interventionJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92000-12-01110PREAI
Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritisDRUG DEVELOPMENT RESEARCHIF4.22000-01-010PREAI